CD274 and neoplasm: Clinical trials, such as KEYNOTE‐048, have shown that the presence of PD‐L1 (with a cut‐off value of ≥ 1%) on both tumor and tumor‐infiltrating immune cells is associated with a better response to therapy [15, 16].